Company Description
TuHURA Biosciences, Inc. operates as a biotechnology company that develops novel cell and gene therapies based on distinct and synergistic technology platforms.
The company owns and develops a product portfolio of cellular and gene therapies that can detect, monitor, and control cancer.
It offers ImmuneFx, a cancer vaccine; Morphogenesis Allograft Tissue with Compatible HLA (MATCH) stem cell banks; Polymer Antibody Cell Separation System (PACS), a device that captures and releases viable targeted cells from large volumes; and BlueBio, a program for mining microbial compounds from the ocean floor.
The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December, 2023.
TuHURA Biosciences, Inc. was incorporated in 1993 and is based in Tampa, Florida.TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc. .
| Country | United States |
| Founded | 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | James Bianco |
Contact Details
Address: 10500 University Center Drive, Suite 110 Tampa, Florida 33612 United States | |
| Phone | 813 875 6600 |
| Website | tuhurabio.com |
Stock Details
| Ticker Symbol | HURA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001498382 |
| ISIN Number | US8989201038 |
| Employer ID | 99-0360497 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. James A. Bianco M.D. | President, Chief Executive Officer and Director |
| Dan Dearborn CPA | Executive Vice President of Finance and Chief Financial Officer |
| Michael Lawman | Co-Founder |
| Patricia Lawman | Co-Founder |
| Michael Krsulich | Head of Quality Assurance |
| Dr. Bertrand Le Bourdonnec Ph.D. | Executive Vice President, Head of Drug Discovery, Early Development, and Program Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2025 | 425 | Filing |
| Apr 1, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 18, 2025 | 8-K | Current Report |
| Mar 12, 2025 | 8-K | Current Report |
| Feb 14, 2025 | 8-K | Current Report |
| Feb 7, 2025 | S-4 | Filing |
| Jan 3, 2025 | 8-K | Current Report |
| Dec 23, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Dec 12, 2024 | 425 | Filing |